NCT03418675View on ClinicalTrials.gov

Brexpiprazole in Borderline Personality Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

December 30, 2020

Study Completion Date

April 14, 2021

Conditions
Borderline Personality Disorder
Interventions
DRUG

Rexulti

Atypical antipsychotic

DRUG

Placebo

Pill that contains no medicine

Trial Locations (1)

60637

University of Chicago, Chicago

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

University of Chicago

OTHER